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Cell uptakePharmacokinetic properties of oligonucleotides are largely driven by chemistry of the backbone and thus are se-
quence independent within a chemical class. Tissue bioavailability (% of administered dose) is assisted by plasma
protein binding that limits glomerular ﬁltration and ultimate urinary excretion of oligonucleotides. The substitu-
tion of one non-bridging oxygen with the more hydrophobic sulfur atom (phosphorothioate) increases both
plasma stability and plasma protein binding and thus, ultimately, tissue bioavailability. Additional modiﬁcations
of the sugar at the 2′ position, increase RNA binding afﬁnity and signiﬁcantly increase potency, tissue half-life and
prolong RNA inhibitory activity. Oligonucleotidesmodiﬁed in this manner consistently exhibit the highest tissue
bioavailability (N90%). Systemic biodistribution is broad, and organs typically with highest concentrations are
liver and kidney followed by bonemarrow, adipocytes, and lymph nodes. Cell uptake is predominantlymediated
by endocytosis. Both size and charge for most oligonucleotides prevents distribution across the blood brain bar-
rier. However, modiﬁed single-strand oligonucleotides administered by intrathecal injection into the CSF distrib-
ute broadly in the CNS. The majority of intracellular oligonucleotide distribution following systemic or local
administration occurs rapidly in just a few hours following administration and is facilitated by rapid endocytotic
uptake mechanisms. Further understanding of the intracellular trafﬁcking of oligonucleotides may provide
further enhancements in design and ultimate potency of antisense oligonucleotides in the future.
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There has been signiﬁcant growth and maturity in the number and
type of oligonucleotide therapeutics being studied in clinical trials
today. The pharmacokinetics and biodistribution of oligonucleotidesery Reviews theme issue on
1 760 603 4650.
. This is an open access article underhas been predominantly published for antisense single-stranded DNA/
RNA oligonucleotides (ASOs) and, to a lesser extent, double-stranded
siRNA. ASOs are synthetic DNA/RNA like oligonucleotides, typically
comprised of 16–21 nucleotides, which bind to RNA through
sequence-speciﬁcWatson-Crick base pair interactions [1] and are high-
ly water soluble (N50mM), stable for years under refrigeration and ad-
ministered in simple saline solutions. Two general chemical classes of
ASOs are commonly used today: (1) single-stranded ASO thatmodulate
RNA function by several mechanisms including degradation of the
target RNA by the enzyme, RNase H, or modulate RNA intermediatethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cleotides that work through an RNA-induced silencing complex (RISC)
to promote degradation of the target RNA [2]. Importantly, ASOs target
RNA in the nucleus (preRNA, mRNA, non-coding RNA, toxic nuclear lo-
calized RNA, etc.) and/or cytoplasm and thus must cross a biological
membrane to exert the desired pharmacology. Once bound to the target
RNA, ASOs or the antisense strand of the siRNA duplex can affect the
metabolism of the target RNA by a number of mechanisms, including
degradation via the recruitment of endogenous RNase H1 recognition
of the RNA/DNA duplex, or in the case of siRNA the RISC complex
[3,4]. ASOs have been developed in numerous chemical classes, most
of which contain phosphorothioate backbones plus one or more 2′-
ribose sugar modiﬁcations (2′-MOE, cEt, LNA, and 2′-OMe) or with
sugar-phosphate modiﬁcations (e.g., morpholino and PNA).
For the purpose of this review, the primary publications available
and used for summarizing the pharmacokinetic properties are for sin-
gle-stranded phosphorothioate modiﬁed chimeric (DNA/2′-modiﬁed)
ASOs (Fig. 1).Where possible, published data fromother classes of com-
poundswill be compared or contrastedwith this class. Oligonucleotides
are distinguished from other classes of pharmaceutical agents by both
the mechanism of action and physical–chemical or pharmaceutical
properties. These distinguishing features provide an opportunity to pur-
sue a large spectrum of ﬁrst-in-class or best-in-class therapeutic agents
for molecular targets that are unreachable by other classes of agents,
e.g., small molecules and antibodies, which predominantly target
proteins.
2. Pharmacokinetic properties of antisense oligonucleotides
The primary route of administration for oligonucleotides for system-
ic applications is by parenteral injection, either intravenous (IV) infusion
or subcutaneous (SC) injection. Following systemic administration,
phosphorothioate-modiﬁed single-stranded ASOs rapidly transfer from
blood into tissues (minutes to hours). Pharmacokinetic properties of
ASOs are similar across species and gender (5–9). Rapid transmission
into cells is predominantly facilitated by endocytotic uptake. Once intra-
cellular, ASOs exhibit long half-lives (2–4weeks) and prolonged activity
in suppressing or altering expression of their target RNA.Fig. 1. Chemistry and structure of 2′-modiﬁed chimeric rnaseh oligonucleotides. The
chimeric RNaseHoligonucleotide is generally designedwith a phosphorothioate backbone
and two regions of 2′-modiﬁed ribose residues on either end of themoleculewhichﬂank a
central DNA region (gap) that supports RNase H activity upon hybridization to a comple-
mentary RNA. This design provides enhanced stability and potency, favorably attenuates
non-hybridization-based toxicities, while supporting sequence-speciﬁc reduction of the
target mRNA. 2′-OMe denotes 2′-O-methyl; MOE, 2′-O-methoxy ethyl; LNA, locked
nucleic acid; S-cEt, (S)-constrained-2′-O-ethyl.2.1. Absorption and distribution following IV/SC administration
Following SC administration, ASOs are rapidly absorbed from the in-
jection site into the circulation with peak plasma concentrations consis-
tently reached within 3 to 4 h [5–9]. Nearly complete absolute
bioavailability has been observed for multiple ASOs after SC administra-
tion in monkeys [5,6]. Following either IV or SC administration, plasma
concentrations rapidly decline from peak concentrations in a multi-
exponential fashion—characterized by a dominant initial rapid distribu-
tion phase wherein drug transfers from circulation to tissues in minutes
or a few hours, followed by a much slower terminal elimination phase
(half-life of up to several weeks). The apparent terminal elimination
rate observed in plasma is consistent with the slow elimination of ASOs
from tissues, indicating equilibrium between post-distribution phase
plasmaconcentrations and tissue concentrations (Fig. 2) [6]. Thepartition
ratios between liver and post-distribution plasma concentrations are
similar across animal species (approximately 5000:1 for 2′-MOE modi-
ﬁed ASOs), and therefore post-distribution plasma concentrations are
also expected to provide a surrogate for tissue exposure in humans [6].
ASOs that contain a phosphorothioate backbone are extensively
bound to plasma proteins (≥85%) across all species [5,9], with albumin
being the protein that appears to bind the greatest amount of the drug
inmost species includingman. Protein binding to albumin is of relative-
ly low afﬁnity thus prevents loss of drug to renal ﬁltration and yet still
facilitates uptake in tissues (Kd approximately 150 μM) [5]. Plasma pro-
tein binding is not saturated at clinically relevant doses due to the large
capacity of binding to proteins in plasma.
In contrast, oligonucleotides that lack charge or are less extensively
or more weakly bound to plasma proteins (peptide nucleic acids
(PNAs),morpholinos, and unmodiﬁed and unformulated siRNA) exhibit
more rapid clearance from blood primarily due to either metabolism in
blood or excretion in urine [10–12]. These compounds and their metab-
olites are readily ﬁltered and excreted, resulting in much lower or neg-
ligible tissue uptake. For these reasons, the kidney (the organ with
highest concentrations of these oligonucleotides) is the primary organ
of distribution but with still very low concentrations [13]. Thus, appro-
priate and balanced plasma protein binding is required for broad and
signiﬁcant delivery to tissues and cells systemically. Either too tightly
bound or not bound enough result in poor distribution properties.
For all animal species evaluated, ASOs distribute broadly into most
tissues with the exception of the central nervous system after systemic
administration, as is the case with all second-generation ASOs (Fig. 3)
[5,15]. The major systemic tissues of distribution include liver, kidney,
bone marrow, adipocytes (cell body but not lipid fraction), and lymph
nodes [5–7,14–18].
2.2. PK/PD: improved potency of ASOs drives antisense activity beyond the
liver and kidney
The broaddistribution of antisense drugs can be exploited to provide
activity in numerous tissue targets outside of liver and kidney. It has
been well understood that where the antisense oligonucleotide accu-
mulates in highest concentrations (liver and kidney), good antisense
activity is routinely observed [13–17]. Nevertheless, antisense activity
has been shown in all tissues of distribution for antisense molecules
(Table 1) [18]. For example, while much less ASO is distributed to
adipose tissue, with potent second-generation chemistry, antisense
activity can be quite robust [19–21].
3. This property has been exploited for the development of cancer
therapies based upon chemical modiﬁcations that increase binding
afﬁnity and thus potency of the antisense drug [22–24]
More recently, it has been demonstrated that antisense drugs can
efﬁciently targetmuscle tissues, which has served as the basis for devel-
oping therapies for muscular dystrophies such as Duchenne muscular
Fig. 2. Two different sequences in the same 2′-MOE chimeric chemical class exhibit different liver and terminal plasma half-lives but similar liver: plasma concentration ratios over time,
consistent with an equilibrium established between tissue and post-distributional plasma drug levels.
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is identiﬁcation of potent molecules, effective at nM or low μM concen-
trations, with broad and optimal biodistribution properties. One can
speculate that the reasons we have seen less than robust pharmacology
in muscle targeted ASOs can be traced to poor tissue bioavailability
coupled with insufﬁcient potency of the constructs utilized [21,28].
Recently, animal studies have demonstrated that potent, well-distributed
ASOs can produce robust and durable pharmacology (as measured by
speciﬁc and nearly complete knockdown of RNA levels) in muscle
[29,30]. Clinical conﬁrmation of these observations is needed to conﬁrm
therapeutic application.
4. Biodistribution following intrathecal administration
Antisense drugs do not cross the intact blood-brain barrier. Howev-
er, delivery of the antisense drugs in the cerebral spinal ﬂuid (CSF) sur-
rounding the spinal cord and brain results in broad distribution into
spinal cord and brain tissue [31–34]. These preclinical ﬁndings have
now been translated to the clinic. Investigators ﬁrst demonstrated safe
and well-tolerated intrathecal administration of a 2′MOE modiﬁed
second-generation ASO in SOD1 familial ALS patients [35]. The
second-generation 2′-MOE ASO targeting SOD1 was administered by
intrathecal infusion over a 12-h period. Maximum concentrations
were measured in CSF and plasma at the end of the infusion. CSF con-
centrations were well-predicted directly from preclinical animal PK
data. The exposure of the drug in blood after direct administration
into CSF was multiple orders of magnitude lower than exposures ob-
served with direct administration by SC or IV administration reﬂectiveFig. 3.ASOs administered systemically distribute broadly to various tissues as demonstratedbyq
single subcutaneous injection of a [35S]-labeled 2 ′-MOE modiﬁed chimeric antisense oligonucof the lower total dose administered and the partial transfer from the
CNS to the systemic circulation [36,37].
Preclinical models have been used to further assess direct adminis-
tration ofmodiﬁed ASOs into cerebrospinal ﬂuid (CSF). It has been dem-
onstrated that bolus injection into the CSF results in better distribution
in the CNS than slow infusion [34]. This paper reports broad distribution
throughout the central nervous system, including all concentrations of
the spinal cord and brain structures in mice and nonhuman primates.
Active uptake into neurons broadly, including motor neurons with ro-
bust antisense activity, has been demonstrated. Distribution kinetics
from the CSF into CNS tissues is rapid with a distribution half-life of
less than 1 h that is likely due to the combination of uptake into CNS tis-
sues and transfer to systemic circulation. Similar to plasma following
systemic dosing, the CSF concentrations of drug exhibit multiphasic ki-
netics with a long terminal half-life at very low concentrations in CSF
that appear to be in equilibrium with central nervous system tissues
(Fig. 4). Once again, there appears to be uptake of oligonucleotides
broadly in multiple cell types in the CNS. Combined with a good clinical
safety proﬁle observed to date, the likely application in neurodegenera-
tive disease alone are broad and has the opportunity to address directly
disease causation in patients that have extremely high unmet need
[34,35,38].
5. Mechanism of cellular uptake of ASOs
Understanding how ASOs trafﬁc into and within cells has the poten-
tial to improve ASO design and ultimately lead to more potent ASO
drugs. In vivo experiments in mice [39] demonstrated that slowlyuantitativewhole body autoradiography (left) and tissue distribution (right) at 48h after a
leotide at a target dose of 25 mg/kg to a male rat.
Table 1
MALAT1 mRNA knock down (% control) in multiple tissues
and organ systems (mouse) following SC administration of a
MALAT1 2′ gapmer cEt (Gen 2.5) antisense oligonucleotide–
quantitative RT-PCR.
Tissues Target Kd (%)
Liver −95
Kidney −97
Adipose −75
Heart −65
Mes LN −61
Diaphragm −50
Brain 0
Duodenum −64
Stomach −55
Lung −86
Adrenal −90
Gall bladder −95
Bladder −51
Prostate −79
Fig. 5. Diagram depicts the theoretical dual cell uptake mechanisms for antisense
oligonucleotides that result in productive and nonproductive intracellular distribution
(ﬁgure adapted from reference [41]).
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take in the liver compared with bolus administration, implicating a sat-
urable uptake process. The lower plasma ASO concentrations presented
to the liver over a longer period of time (via infusion) allowed a larger
amount to be taken into cells. However, there was little to no ASO activ-
ity associated with the higher concentrations in liver suggesting that a
nonproductive uptake pathways exists in cells that endocytose ASOs
presented at slow and low concentrations [39]. Thus, better productive
uptake in vivo (liver in this case) was facilitated by bolus injection of
ASOs that we speculate may overcome the saturable nonproductive
pathway. Competition of the nonproductive pathways with nonsense
ASOs resulted in less bulk uptake in liver with paradoxically greater an-
tisense activity as measured by target RNA silencing [39] with lower
total exposure. In composite, this work suggests at least two pathways
of uptake in cells in vitro and in vivo, one leading to productive anti-
sense activity and the other resulting sequestration (nonproductive up-
take) of the ASO (Fig. 5). Understanding early endosome uptake and
sorting pathways may unlock the mechanism of these observations.
Further, intracellular protein binding may be associated with localiza-
tion or trafﬁcking of phosphorothioate ASOs [40].
Ex vivo primary hepatocytes readily and productively take up ASOs
and exhibit robust RNA inhibition in culture without transfection but
rapidly lose this ability likely due to loss of transporter expression. To
better understand the mechanism of transfection-free uptake intoFig. 4. ASOs with 2′-MOE modiﬁcations administered intrathecally by lumbar puncture
bolus injection to the CSF of monkeys distribute rapidly to CNS spinal cord tissues with
subsequent transfer to systemic circulation and exhibit long half-lives of multiple months
in CSF, plasma, and CNS tissues requiring infrequent dose administration.cells [41], we identiﬁed a stable mouse hepatocyte cell line (MHT)
that take up single-stranded ASOs productively by free uptake in simple
aqueous buffer solutions without transfection agents [41]. The study of
ASO uptake in these cells implicates endocytosis as the dominant
uptake mechanism requiring binding to surface proteins. Further, the
importance of DNA in the productive uptake of oligonucleotides was
conﬁrmed, where both the base and the deoxy sugar were required
for optimal uptake. Nanomolar concentrations of ASOs taken up by
endocytosis were shown to reduce target RNAs within hours withmax-
imal knockdown apparent by 24 h, which are similar to in vivo observa-
tions. Microscopy imaging demonstrated that the bulk ASO found in the
cells is immediately and predominately associated with intracellular
vesicular structures consistent with lysosomes.
Additional work in the MHT cells and in vivo has identiﬁed AP2M1
as an important clathrin-associated adaptor protein for active or pro-
ductive free uptake of ASOs [41]. Paradoxically, the knockdown of
clathrin did not alter productive uptake of ASOs, thus suggesting the ac-
tive pathway is an as-yet uncharacterized clathrin-independent but
AP2M1-dependent pathway. As we better understand the pathways
that result in efﬁcient delivery to intracellular active compartments
and perhaps even more clearly understand the vesicular processing
pathways in the cell, we have an opportunity to better design ASOs
to highest potential potency. Further work to understand endosomal
vesicular sorting and ASO trafﬁcking is ongoing.
5.1. Optimizing cellular biodistribution through receptor targeting
Recent progress in identiﬁcation and utilization of ligand conjuga-
tion strategies conﬁrm that potency can be substantially improved
through more efﬁcient uptake in the target cell. Triantennary GalNAc
conjugates of siRNA or single-stranded antisense molecules have great-
ly enhanced the targeted distribution of thesemolecules to hepatocytes
and resulted in signiﬁcant improvements in potency [42,43]. In general,
liver (and speciﬁcally hepatocyte) distribution and activity is enhanced
approximately 10-fold with concomitant reductions in distribution to
other organs and cell types (Fig. 6). Increased potency of these mole-
cules, as manifested by reduction of target mRNA at much lower doses
Fig. 6.GalNAc conjugation to single-stranded chimeric ASOs produces orders ofmagnitude
greater potency in vivo (mouse) for reducing hepatocytemRNA targets (example for SRB1
mRNA) with up to a 100-fold decrease in the mg/kg dose of ASO needed to effect a 50%
reduction in mRNA compared to SRB1-C (2′MOE ASO). SRB1-C-1′MOE chimeric ASO;
SRB1-M-cEt chimeric ASO; GN3-GalNAc conjugate.
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tocyte.While this speciﬁc ligandappears limited to hepatocyte targeting,
it nevertheless points the way to potential optimization for other cell
types through cell-speciﬁc endocytotic pathways.
6. Conclusion
Pharmacokinetic properties and biodistribution of oligonucleotides
are largely driven by chemistry of the backbone and thus are sequence
independent within a chemical class. In particular, chemical modiﬁca-
tions in sugar chemistry (2′MOE, 2′OMe, LNA or cEt) or base chemistry
have much less effect on the pharmacokinetic properties than does the
overall charge at the phosphate bridge in the backbone (PS vs PO vs
morpholino). Tissue bioavailability (% of administered dose) is assisted
by plasma protein binding that limits glomerular ﬁltration and ultimate
urinary excretion of oligonucleotides. The substitution of one non-
bridging oxygen with sulfur (phosphorothioate) increases both plasma
stability and plasma protein binding. Additional modiﬁcations of sugars
at the 2′ position increase RNA binding afﬁnity and signiﬁcantly in-
crease tissue half-life andprolongRNA inhibitory activity and ultimately
canmodulate protein binding. Oligonucleotidesmodiﬁed in thismanner
consistently exhibit the highest tissue bioavailability (N90%). Plasma
protein binding of 2′-MOE and PS modiﬁed oligonucleotides has been
shown to be of relatively low afﬁnity (μM), prevents renal ﬁltration,
while enhancing distribution to tissues and into cells. Systemic
biodistribution is broad, and organs typically with highest concentra-
tions are clearance organs, liver, and kidney followed by bone marrow,
adipocytes, and lymph nodes. Both size and charge for most oligonucle-
otides prevents distribution across the blood brain barrier. However,
modiﬁed single-strand oligonucleotides administered by intrathecal
injection into the CSF distribute broadly in the CNS. The great majority
of intracellular oligonucleotide distribution systemically or in the CNS
occurs rapidly in just a few hours following administration and is facili-
tated by rapid endocytotic uptake mechanisms. Both systemically andwithin the CNS tissues of distribution, cells differentially take up oligo-
nucleotides. The conjugation of triantennary GalNAc ligands that direct
ASOs or siRNA to cell-speciﬁc endocytotic receptors on hepatocytes
has been shown to alter distribution and enhance potency for targets
in hepatocytes. Further understanding of vesicular sorting and the intra-
cellular trafﬁcking of oligonucleotidesmay provide substantial enhance-
ments in design and ultimate potency of antisense oligonucleotides in
the future.
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